Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.83Last Year’s EPS
2.29Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: -20.80%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging landscape with significant declines in the Life Science segment and impacts from China policy changes, despite meeting some financial targets and strategic acquisitions. The overall sentiment is cautious with a focus on future improvement.Company Guidance
During the Bio-Rad Laboratories, Inc. fourth quarter and full year 2024 results conference call, the company provided guidance for 2025, anticipating a currency-neutral revenue growth of 1.5% to 3.5%, excluding acquisitions. The guidance reflects challenges such as a 60 basis point reduction in gross margin due to reimbursement changes for diabetes testing in China and a 40 basis point impact from foreign currency fluctuations. The Life Science Group's revenue is expected to grow 1.5% to 3.5%, bolstered by high single-digit growth in process chromatography. The Clinical Diagnostics Group is projected to increase between 2% and 3%, despite a 100 basis point impact from a partner's exit from the donor screening business and the aforementioned diabetes testing changes. The company aims for a full-year non-GAAP gross margin between 55% and 55.5% and a non-GAAP operating margin between 13% and 13.5%. Additionally, Bio-Rad plans to achieve key development milestones, such as its anticipated acquisition of Stilla Technologies, which should complement its digital PCR portfolio, with the transaction expected to close by the end of Q3 2025.Successful 2024 Revenue and Operating Margin Targets
Bio-Rad Laboratories met its revised 2024 guidance for both revenue and operating margin, with the clinical diagnostic business performing slightly better than forecasted.
Gross Margin Expansion
Gross margin improved in 2024 due to productivity improvements, lean initiatives in manufacturing sites, and effective cost management.
Binding Offer to Acquire Stilla Technologies
Bio-Rad entered into a binding offer to acquire Stilla Technologies, which is expected to complement its digital PCR portfolio and enhance product strategy.
Strong Demand for Droplet Digital PCR Portfolio
Strong demand for reagents and consumables in the droplet digital PCR portfolio, with low double-digit growth year over year.
Increased Free Cash Flow
Free cash flow for the full year of 2024 was approximately $290 million, up from $218 million in 2023.
---
BIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $306.36 | $277.16 | -9.53% |
| Oct 30, 2024 | $330.58 | $358.19 | +8.35% |
| Aug 01, 2024 | $341.25 | $335.93 | -1.56% |
| May 07, 2024 | $279.91 | $268.26 | -4.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIO EPS forecast?
BIO EPS forecast for the fiscal quarter 2025 (Q1) is 1.83.
---